NCT02964013 2025-10-14
KEYVIBE-001
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
9 trialsNCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01450761 2020-07-08
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Bristol-Myers Squibb
Phase 3 Completed
NCT00927875 2013-06-03
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00621361 2012-12-17
Phase I Safety and Tolerability Study of Cediranib (RECENTINâ„¢, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
AstraZeneca
Phase 1 Completed
NCT00191139 2010-02-17
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed